Aim of this work is to verify the farmaceutical form of oral Budesonide compounded used in Chron’s disease: capsules delay release or oral suspension. In particular way the kinds of excipients or bases-veicle used in the galenic pharmacy. The therapeutic need require a release of the API in delayed release. The Budesonide show low systemic impacts due by its hepatic methabolism vs a tocipal effect useful in this pathology. Some formulation provided by various pharmacy are reported as well as new technology like the 3D-PRINTING systems for colonic targeting tablets.